Announcements - OBI Pharma 台灣浩鼎

2022.Aug.31

Announcement on behalf of AP Biosciences that preemptive rights forfeited by all directors are over 50% and made available to specific persons

2022.Aug.31

Announcement on behalf of AP Biosciences’ call period of 2022 cash capital increase

2022.Aug.12

Announcement on behalf of AP Biosciences to file application for Phase I human clinical trial of Bispecific Antibody, AP203, to US FDA

2022.Aug.11

Announcement of amendment of the Company's 2021 Annual Report

2022.Aug.08

Announcement on behalf of AP Biosciences that preemptive rights forfeited by directors are over 50% and made available to specific persons

2022.Aug.08

Announcement that the cumulative reduction of shareholding in major subsidiary, AP Biosciences, has reached more than 10%

2022.Aug.08

OBI forfeits subscription of AP Biosciences’ cash capital increase, distributes rights to its shareholders and sets target date

2022.Aug.08

The Company’s BOD resolved to forfeit the subscription of AP Biosciences’ cash capital increase and distribute the rights to its shareholders

2022.Aug.08

OBI’s BOD resolved employees and amount granted for the first issuance of RSU and authorized the decision of record date to the Chairman

2022.Aug.08

The Company's Board of Directors approved the amendment of 2022 Restricted Stock Awards Issuance Rules

News

Latest News

Events

Latest events